Get the Stockscreener App
18.52
147.26%
11.03
After Hours:
19.44
0.92
+4.97%
Wave Life Sciences Ltd stock is traded at $18.52, with a volume of 145.77M.
It is up +147.26% in the last 24 hours and up +135.62% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$7.49
Open:
$12.825
24h Volume:
145.77M
Relative Volume:
30.73
Market Cap:
$3.10B
Revenue:
$93.95M
Net Income/Loss:
$-129.87M
P/E Ratio:
-20.58
EPS:
-0.9
Net Cash Flow:
$-202.88M
1W Performance:
+149.93%
1M Performance:
+135.62%
6M Performance:
+156.51%
1Y Performance:
+21.28%
1-Day Range:
$12.72
$19.60
1-Week Range:
$6.93
$19.60
52-Week Range:
$5.28
$19.60
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
18.52 | 1.25B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.04 | 115.56B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.26 | 75.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.02 | 60.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.76 | 55.48B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.55 | 43.51B | 447.02M | -1.18B | -906.14M | -6.1812 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences Soars 147% on Breakthrough “Targeted Fat Loss” Drug Data - NAI500
Nvidia, AMD, Wave Life Sciences, Toll Brothers And Carvana: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Why Wave Life Sciences Stock Vaulted 146% Higher on Monday - Yahoo Finance
Why Wave Life Sciences Stock Vaulted 146% Higher on Monday - The Motley Fool
Wave (WVE) Shows Promising Phase 1 Results in Obesity Study - GuruFocus
Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Insider Monkey
Wave Life Sciences (WVE) Launches $250 Million Public Offering - GuruFocus
Wave Life Sciences announces $250M public offering and pre-funded warrants - MSN
Wave Life Sciences Launches $250 Million Stock, Warrant Offering - marketscreener.com
Wave Life Sciences (WVE) Stock: Holds Steady as WVE-007 Shows Promising Obesity Treatment Results - parameter.io
Wave Life Sciences announces $250 million public offering - Investing.com
Wave Life Sciences Explodes Higher On Preliminary WVE-007 Body Composition Results (NASDAQ:WVE) - Seeking Alpha
Wave Life Sciences (Nasdaq: WVE) begins $250M share and pre-funded warrant sale - Stock Titan
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
Wave Life skyrockets on obesity drug trial, Strategy buys bitcoin - Yahoo Finance
Raymond James raises Wave Life Sciences stock price target to $21 - Investing.com UK
Wave Life Sciences’ WVE-007: Promising Data and Safety Profile Elevate Buy Rating and Price Target - TipRanks
WVE Stocks on the Rise: Key Insights - StocksToTrade
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Leerink Partners raises WAVE Life Sciences stock price target to $28 on promising results - Investing.com
Wave Life Sciences (WVE): Assessing Valuation After Recent Share Price Weakness and Long-Term Gains - Yahoo Finance
Why Is Wave Life Sciences Stock Skyrocketing Monday?WAVE Life Sciences (NASDAQ:WVE) - Benzinga
Wave Life Sciences Stock (WVE) Soars 135% on Obesity Drug Results - TipRanks
Wave Life Sciences (WVE) Stock Surges as Obesity Drug Shows Promising Fat Loss Results - parameter.io
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpWhat's Next? - MarketBeat
Stocks making the biggest moves midday: Paramount Skydance, Wave Lifesciences, Confluent & more - CNBC
Paramount Skydance, Wave Life Sciences, Ocular… - inkl
Wave Life Sciences Shares Rise After Phase 1 Interim Data on Obesity Drug Candidate - marketscreener.com
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th - Yahoo Finance
Wave Life, Structure and Ascletis post wins in obesity management - BioWorld MedTech
Wave Life Sciences (WVE) Shares Bolstered by Promising Trial Results - GuruFocus
Wave Life Sciences stock hits 52-week high at $15.75 By Investing.com - Investing.com Australia
Wave Life Sciences (WVE) Surges on Promising Obesity Therapy Res - GuruFocus
Wave Life Sciences stock hits 52-week high at $15.75 - Investing.com
Wave Life Sciences Stock Rockets 120% After Obesity Drug Shows Deep Fat Reduction, Muscle Gain — Traders See A ‘Blockbuster' Candidate - Stocktwits
Wave Life Sciences closes up 147% on positive early data from obesity drug trial - Seeking Alpha
This Company Says It Can Target Fat Loss. Shares Skyrocket. - Investor's Business Daily
Market movers: CoreWeave, Netflix, Paramount, Confluent, Wave Life Science… - Proactive financial news
Wave Life Sciences’ Surge: Analyzing Recent Movements - timothysykes.com
Wave Life Sciences Says Phase 1 Interim Data of WVE-007 to Treat Obesity Showed Body Composition Improvement - marketscreener.com
Wave Life Sciences surges after positive data for its weight-loss drug - TradingView
Wave Life Sciences Announces Positive Phase 1 Trial Results - TipRanks
Wave Life Sciences (WVE) Shows Promising Results in Obesity Tria - GuruFocus
Wave Life Sciences stock surges on promising obesity drug data By Investing.com - Investing.com UK
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss - The Manila Times
Wave Life Sciences stock surges on promising obesity drug data - Investing.com
Wave Life Sciences reports positive results for obesity treatment - Investing.com
Wave Life Sciences Ltd Announces Positive Interim Data from INLIGHT Trial - TradingView
Wave Life Sciences reports positive results for obesity treatment By Investing.com - Investing.com UK
Wave Life Sciences announces positive interim data from phase 1 inlight trial of WVE-007 for obesity - marketscreener.com
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):